The phone calls from American buyers haven’t stopped. Neither have the shipments. For many Singapore-based companies with exposure to the United States, the Trump administration’s 10% baseline tariff — widely feared when it landed in April 2025 — has turned out to be, as more than one founder has privately put it, something they can live with. The margin hit is real. The commitment to the US market is, for now, intact.

This isn’t naivety. Singapore’s business class is too wired into global trade to mistake inconvenience for catastrophe. What the past twelve months have revealed, instead, is a calibrated judgement: that America’s consumer base, its legal predictability, and its sheer scale still make it the world’s most attractive destination, tariff or no tariff.

Why Singapore’s Export Sector Held Up Better Than Expected

When the White House announced its sweeping reciprocal tariffs on April 2, 2025 — quickly dubbed “Liberation Day” — Singapore found itself in an unusual position. The city-state was handed the lowest rate in Southeast Asia: a 10% baseline, compared with 19% to 40% for neighbours like Vietnam, Indonesia, and Cambodia. This was in spite of Singapore holding a free trade agreement with Washington that had been in force since January 2004 — and despite the US actually running a goods trade surplus with Singapore.

That anomaly still rankles in Singapore’s government corridors. According to the US Trade Representative, the US goods trade surplus with Singapore reached $3.6 billion in 2025, up from $1.9 billion in 2024 — a near-doubling that makes the tariff’s rationale increasingly hard to justify on balance-of-payments grounds. In March 2026, Singapore’s trade ministry went public with its dispute of American trade data, arguing the official US figures misrepresent the bilateral picture.

Yet even with the duty in place, Singapore’s companies did something that surprised economists who had modelled for a significant contraction: they adapted and, in many cases, pushed on. The Ministry of Trade and Industry upgraded Singapore’s 2025 GDP forecast to around 4% in November — well above the 1.5% to 2.5% initially pencilled in — citing stronger semiconductor exports driven by the AI boom and unexpected resilience among trading partners. Full-year growth came in at 4.8%.

The US remains Singapore’s second-largest export destination, absorbing roughly 11% of the Republic’s domestic exports in 2024. Companies have not abandoned that relationship. Many have leaned into it harder, viewing tariff disruption elsewhere in Asia as a relative advantage.

A Manageable Levy, But Not a Costless One

How are Singapore companies dealing with US tariffs? The short answer is: largely by absorbing part of the cost, passing some on, and restructuring faster than anyone expected.

A March 2025 survey by the American Chamber of Commerce in Singapore found that most respondents planned to pass tariff-related costs through to US customers, while simultaneously accelerating supply chain diversification. This dual-track response reflects a broader strategic logic: protect the American relationship in the near term while reducing single-market dependency over a longer horizon.

What that looks like on the ground varies by sector. Manufacturers in precision engineering — a bright spot identified by MTI in its August 2025 briefing — have continued ramping up capital investment in AI-related semiconductor production, insulated partly by the global demand surge from data centre buildouts. These firms aren’t debating whether to serve the US market. They’re debating how to remain irreplaceable within it.

The picture is more complicated for smaller companies working with thinner margins. Nomura analysts reported in September 2025 that Singapore exporters were absorbing more than 20% of US tariff costs directly — a real and sustained squeeze. Still, for a 10% levy applied to goods that clear US customs at high average selling prices, the maths often still work. A Singapore med-tech firm shipping precision instruments at $15,000 per unit absorbs a very different blow than, say, a Vietnamese garment exporter facing a 32% rate on $8 t-shirts.

The relevant comparison isn’t between tariff and no-tariff Singapore. It’s between Singapore at 10% and its regional competitors at 19% to 40%. On that basis, the commercial case for the US market hasn’t collapsed. It’s narrowed — which is why the companies still in the game are typically those with the product quality to justify the premium or the brand equity to pass costs through.

The Sectoral Flashpoints: Pharma and Chips

Singapore’s composure at the aggregate level masks genuine alarm in two sectors that define its high-value export identity: pharmaceuticals and semiconductors.

Singapore ships approximately S$4 billion (US$3.1 billion) worth of pharmaceutical products to the United States each year. These are mostly branded drugs — sophisticated, high-value formulations — which faced a threatened 100% tariff unless manufacturers established a physical US manufacturing presence. That threat, announced as part of Trump’s sectoral tariff push, is currently on hold pending negotiations and exemption applications. But it has not disappeared. Deputy Prime Minister and Trade Minister Gan Kim Yong acknowledged in September 2025 that negotiations with Washington over both pharma and semiconductors were ongoing, with an “arrangement to allow us to remain competitive in the US market” still the goal rather than the outcome.

Minister Gan Siow Huang confirmed in October 2025 that a significant number of Singapore-based pharmaceutical firms are pausing US expansion decisions pending tariff clarity — a rational hold on capital allocation, not a signal of retreat. The broader concern, articulated by Gan Kim Yong, is longer-range: that escalating tariffs globally could divert investment away from Singapore toward the United States, draining capital that might otherwise have flowed into the region.

In semiconductors, Singapore’s position is partially protected by the AI-driven global demand spike. The precision engineering cluster saw continued investment ramp-ups through 2025, with MTI noting the “sustained shift towards higher value-added” activity as a structural buffer. Yet Section 232 sectoral tariffs on chips — not yet imposed but actively discussed in Washington — remain a latent risk that keeps Singapore’s trade negotiators in near-permanent engagement with US counterparts.

The Case Against Optimism: What the Bears Are Right About

It would be a misreading of Singapore’s resilience to treat it as vindication of the tariff-and-carry-on school of thought. The firms that are pressing ahead in the US market are, almost uniformly, those with structural advantages that most companies don’t have: high average selling prices, proprietary technology, brand recognition, or an irreplaceable position within a US supply chain.

For smaller Singapore companies — the SMEs that account for roughly two-thirds of the city-state’s workforce — the calculus looks different. EnterpriseSG acknowledged in early 2026 that tariffs would “continue to be a looming concern for a long time,” with sectoral duties on semiconductors and pharmaceuticals a persistent threat and the risk of trade diversion from tariff-hit neighbours an additional drag.

What tariff rate does Singapore face from the United States?

Singapore faces a 10% baseline US tariff — the lowest in Southeast Asia — under the Trump administration’s reciprocal tariff framework, despite a free trade agreement in force since 2004 and a US goods trade surplus of $3.6 billion in 2025. A further increase to 15% under Section 122 was announced in February 2026.

Government support has materialised, but its scope has limits. The Business Adaptation Grant, launched in October 2025, offers up to S$100,000 per company with co-funding required — meaningful for a one-person fintech studio rethinking its US go-to-market, but insufficient to offset the structural cost pressures facing an electronics manufacturer running US$50 million in American revenue. SMEs receive a higher support quantum; the grant’s architects acknowledge it can’t reach every firm.

There is also a timing question. Singapore’s 2025 outperformance was partly a function of front-loading: companies rushed exports in the first half of the year ahead of anticipated tariff escalation, driving a 13% NODX rebound in June that flattered the headline numbers. Strip out front-loading, and the structural growth trajectory is more modest. MTI has already warned that 2026 growth — forecast in the 1% to 3% range — will feel meaningfully different from 2025’s AI-and-front-loading-driven surge.

What follows, however, is not necessarily contraction. It is normalisation under a genuinely higher-tariff world — a world Singapore’s companies are, by now, better equipped to navigate than they were fourteen months ago.

The Structural Bet: Singapore’s Long-Term US Positioning

Singapore’s most consequential strategic response to Trump’s tariff regime has not been lobbying Washington or diversifying away from the US. It’s been doubling down on what makes Singaporean goods hard to replace: quality, reliability, and an institutional environment that American buyers trust.

Prime Minister Lawrence Wong has been careful not to overstate the resolution of US-Singapore trade talks, noting as recently as late 2025 that negotiations were at “a very early stage” on pharmaceuticals. But the underlying posture of Singapore’s business community — captured in a UOB Business Outlook Study from May 2025 — is instructive: eight in ten Singapore companies planned overseas expansion within three years, with North America among the markets specifically flagged by consumer goods and industrial firms despite the tariff environment.

That appetite reflects something the macro data alone can’t show. Many Singapore companies with US exposure have been building American relationships for decades. They know their buyers personally. They’ve invested in US certifications, US-compatible regulatory frameworks, US distribution networks. Walking away from that at a 10% tariff rate would mean writing off infrastructure that cost more than 10% to build.

The more profound question is whether the next generation of Singapore companies — those deciding now where to build their first international footprint — will make the same American bet their predecessors did. The EnterpriseSG data on market diversification is notable: in 2025, the agency helped Singapore companies enter 76 new markets — the broadest footprint in five years. Angola. Fiji. Markets that would have been afterthoughts in 2019.

The US isn’t losing its primacy in Singapore’s commercial imagination. But it is, for the first time in a generation, being weighed against alternatives in a way that feels genuinely open. That shift is subtle. It may also be durable.

There is a version of this story where 10% is, in fact, nothing — where Singapore’s companies absorb a manageable cost, keep their American relationships intact, and emerge from the tariff era with their US market share preserved or even expanded as higher-levied competitors retreat. That version is not impossible. Several major firms are living it.

But the more honest reading of the past twelve months is that Singapore’s business community has proved something more modest and more instructive: not that tariffs don’t matter, but that they don’t automatically determine outcomes. What matters, still, is whether you have something the American market genuinely wants. For companies that do, the levy is a tax on success. For those that don’t, it’s an exit ramp. The US market is sorting Singapore’s exporters, quietly and efficiently, in exactly the way markets always have.